For research use only. Not for therapeutic Use.
PD173952 is a tyrosine kinases inhibitor with IC50s of 0.3, 1.7 and 6.6 nM against Lyn, Abl and Csk, respectively. PD173952 is also a potent Myt1 kinase inhibitor with a Ki of 8.1 nM. PD173952 induces apoptosis[1][2].
PD173952 (0-1000 nM; 12 h) inhibits tyrosine phosphorylation of p210Bcr-Abl and CrkL in K562 cells in a concentration-dependent manner[1].
PD173952 (0.5 μM; 1-4 days) inhibits K562 cell viability[1].
PD173952 (0.5 μM; 24 and 48 h) induces apoptosis of K562 and MEG-01 cells[1].
| Catalog Number | R051793 |
| CAS Number | 305820-75-1 |
| Synonyms | 6-(2,6-dichlorophenyl)-8-methyl-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidin-7-one |
| Molecular Formula | C24H21Cl2N5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H21Cl2N5O2/c1-30-22-15(13-18(23(30)32)21-19(25)3-2-4-20(21)26)14-27-24(29-22)28-16-5-7-17(8-6-16)31-9-11-33-12-10-31/h2-8,13-14H,9-12H2,1H3,(H,27,28,29) |
| InChIKey | XZEJMVDCQZRHLN-UHFFFAOYSA-N |
| SMILES | CN1C2=NC(=NC=C2C=C(C1=O)C3=C(C=CC=C3Cl)Cl)NC4=CC=C(C=C4)N5CCOCC5 |
| Reference | [1]. Dorsey JF, et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia. 2002 Sep;16(9):1589-95. [2]. Wichapong K, et al. Application of docking and QM/MM-GBSA rescoring to screen for novel Myt1 kinase inhibitors. J Chem Inf Model. 2014 Mar 24;54(3):881-93. |
